← Leaderboards
Karen A Norris
University Of Pittsburgh At Pittsburgh
$27,323,771
Attributed
$28,690,924
Total exposure
18
Grants
12
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.2M · FY2005–24$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$28,690,924 · 18
By mechanism
R01$19,196,497 · 8
P01$6,554,859 · 3
R56$2,290,454 · 3
R21$356,675 · 1
R41$272,439 · 1
R13$20,000 · 1
Top collaborators
- Stephen Y Chan4 shared
- Michael Robert Downes1 shared
- Alison Morris1 shared
Most similar at University Of Pittsburgh At Pittsburgh
Same institution · by research overlap
- Walter F Good$2,842,687
- Derek C Angus$17,409,826
- Timothy Edward Corcoran$4,686,288
- Stephen Garoff$1,346,334
- Andrea Gambotto$6,859,177
Others in their field
Top investigators on “Lung”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$372,040,227
- Chanza Baytop · Westat, Inc.$271,217,917
- Richard K. Wilson · Washington University$201,818,043
- Walter John Curran · Thomas Jefferson University$112,093,071
Research focus
LungInfectionNonhuman PrimateAnimalsPreventionPrimatesMacacaImmune ResponseHiv InfectionsResponsePreventImmuneChronic Obstructive Airway DiseaseMorbidity - Disease RateLung DiseasesChronicVaccinesAnimal ModelImmunizationPathogenesisPneumocystisClinical TrialsEvaluationRodent Model
Grant awards (63)
Prevention and Treatment of Pneumocystis Pneumonia$754,801
R01 · FY2024 · AI · contact PI
Evaluation of pregnancy on vaccine-induced immunity and protection in a pre-clinical model of RSV infection$766,079
R01 · FY2023 · AI · contact PI
Prevention and Treatment of Pneumocystis Pneumonia$754,801
R01 · FY2023 · AI · contact PI
Evaluation of pregnancy on vaccine-induced immunity and protection in a pre-clinical model of RSV infection$768,859
R01 · FY2022 · AI · contact PI
Prevention and Treatment of Pneumocystis Pneumonia$729,942
R01 · FY2022 · AI · contact PI
Evaluation of pregnancy on vaccine-induced immunity and protection in a pre-clinical model of RSV infection$771,241
R01 · FY2021 · AI · contact PI
Prevention and Treatment of Pneumocystis Pneumonia$729,942
R01 · FY2021 · AI · contact PI
Evaluation of pregnancy on vaccine-induced immunity and protection in a pre-clinical model of RSV infection$780,524
R01 · FY2020 · AI · contact PI
Prevention and Treatment of Pneumocystis Pneumonia$743,912
R01 · FY2020 · AI · contact PI
Molecular Drivers of Vascular Stiffness and Metabolic Dysfunction in HIV-Induced Pulmonary Arterial Hypertension$412,816
R01 · FY2020 · HL
Development of a vaccine to prevent Pneumocystis pneumonia$272,439
R41 · FY2020 · AI
Evaluation of pregnancy on vaccine-induced immunity and protection in a pre-clinical model of RSV infection$786,606
R56 · FY2019 · AI · contact PI
Immunopathogenesis of HIV-associated pulmonary hypertension$721,172
R01 · FY2019 · HL · contact PI
Molecular Drivers of Vascular Stiffness and Metabolic Dysfunction in HIV-Induced Pulmonary Arterial Hypertension$499,098
R01 · FY2019 · HL
Immunopathogenesis of HIV-associated pulmonary hypertension$807,583
R01 · FY2018 · HL · contact PI
Molecular Drivers of Vascular Stiffness and Metabolic Dysfunction in HIV-Induced Pulmonary Arterial Hypertension$756,459
R01 · FY2018 · HL
Molecular Drivers of Vascular Stiffness and Metabolic Dysfunction in HIV-Induced Pulmonary Arterial Hypertension$773,494
R01 · FY2017 · HL
Immunopathogenesis of HIV-associated pulmonary hypertension$729,401
R01 · FY2017 · HL · contact PI
Immunopathogenesis of HIV-associated pulmonary hypertension$80,226
R01 · FY2017 · HL · contact PI
Immunopathogenesis of HIV-associated pulmonary hypertension$749,651
R01 · FY2016 · HL · contact PI
Non-human primate core$680,898
P01 · FY2015 · HL · contact PI
Pre-clinical animal models of PAH$431,570
P01 · FY2015 · HL · contact PI
Vaccine strategies against pneumocystis in non-human primates$182,369
P01 · FY2015 · HL · contact PI
Non-human primate core$667,280
P01 · FY2014 · HL · contact PI
Immune dysfunction and pulmonary hypertension in primate model of HIV infection$516,531
R56 · FY2014 · HL · contact PI
Pre-clinical animal models of PAH$451,284
P01 · FY2014 · HL · contact PI
Immune dysfunction and pulmonary hypertension in primate model of HIV infection$238,463
R56 · FY2014 · HL · contact PI
Vaccine strategies against pneumocystis in non-human primates$167,834
P01 · FY2014 · HL · contact PI
Non-human primate core$648,215
P01 · FY2013 · HL · contact PI
Pre-clinical animal models of PAH$457,999
P01 · FY2013 · HL · contact PI
Vaccine strategies against pneumocystis in non-human primates$163,039
P01 · FY2013 · HL · contact PI
Pittsburgh Lung Conference 2013: Acute and chronic lung infections: Novel patho$20,000
R13 · FY2013 · HL
Non-human primate core$680,898
P01 · FY2012 · HL · contact PI
Pre-clinical animal models of PAH$487,144
P01 · FY2012 · HL · contact PI
Vaccine strategies against pneumocystis in non-human primates$171,259
P01 · FY2012 · HL · contact PI
Serologic memory and prevention of Pneumocystis-related COPD in AIDS macaque mode$748,854
R56 · FY2011 · AI · contact PI
Non-human primate core$695,898
P01 · FY2011 · HL · contact PI
Pre-clinical animal models of PAH$493,017
P01 · FY2011 · HL · contact PI
Vaccine strategies against pneumocystis in non-human primates$176,155
P01 · FY2011 · HL · contact PI
Immune response to Pneumocystis in simian model of AIDS$381,682
R01 · FY2009 · HL · contact PI
Pneumocystis and COPD in a Simian Model of AIDS$370,197
R01 · FY2009 · HL · contact PI
Immune response to Pneumocystis in simian model of AIDS$580,262
R01 · FY2008 · HL · contact PI
Pneumocystis and COPD in a Simian Model of AIDS$370,197
R01 · FY2008 · HL · contact PI
T. cruzi immune evasion factors and vaccine design$176,627
R21 · FY2008 · AI · contact PI
Immune response to Pneumocystis in simian model of AIDS$564,003
R01 · FY2007 · HL · contact PI
Pneumocystis and COPD in a Simian Model of AIDS$370,197
R01 · FY2007 · HL · contact PI
T. cruzi immune evasion factors and vaccine design$180,048
R21 · FY2007 · AI · contact PI
Immune response to Pneumocystis in simian model of AIDS$448,684
R01 · FY2006 · HL · contact PI
Pneumocystis and COPD in a Simian Model of AIDS$381,254
R01 · FY2006 · HL · contact PI
Immune response to Pneumocystis in simian model of AIDS$419,584
R01 · FY2005 · HL
Pneumocystis and COPD in a Simian Model of AIDS$390,430
R01 · FY2005 · HL
Complement Regulation in Trypanosoma Cruzi$293,724
R01 · FY2005 · AI
Complement Regulation in Trypanosoma Cruzi$293,820
R01 · FY2004 · AI
Complement Regulation in Trypanosoma Cruzi$294,801
R01 · FY2003 · AI
Complement Regulation in Trypanosoma Cruzi$266,347
R01 · FY2002 · AI
PNEUMOCYSTIS CARINII PNEUMONIA MODEL IN RHESUS MACAQUES$50,000
R01 · FY2002 · HL
TRYPANOSOMA CRUZI COMPLIMENT$0
P41 · FY2002 · RR
TRYPANOSOMA CRUZI COMPLIMENT$0
P41 · FY2002 · RR
PNEUMOCYSTIS CARINII PNEUMONIA MODEL IN RHESUS MACAQUES$438,172
R01 · FY2001 · HL
Complement Regulation in Trypanosoma Cruzi$266,913
R01 · FY2001 · AI
TRYPANOSOMA CRUZI COMPLIMENT$0
P41 · FY2001 · RR
PNEUMOCYSTIS CARINII PNEUMONIA MODEL IN RHESUS MACAQUES$439,792
R01 · FY2000 · HL
COMPLEMENT REGULATION IN TRYPANOSOMA CRUZI$246,437
R01 · FY2000 · AI